Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

(2019) David Wyles et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: a systematic review and meta-analysis

(2019) Xiaoyun Wang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

(2018) Tarik Asselah et al.   Clinical Gastroenterology and Hepatology

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

(2018) Jürgen K Rockstroh et al.   CLINICAL INFECTIOUS DISEASES

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018

(2018) Maria C. Sorbo et al.   DRUG RESISTANCE UPDATES

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

(2018) Nancy Reau et al.   HEPATOLOGY

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

(2018) Fred Poordad et al.   HEPATOLOGY

Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection

(2018) S. Gupta et al.   JOURNAL OF VIRAL HEPATITIS

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

(2018) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

(2018) Preethi Krishnan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens

(2018) Norio Akuta et al.   JOURNAL OF MEDICAL VIROLOGY

Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?

(2018) Jee-Fu Huang et al.   Expert Review of Anti-Infective Therapy

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures

(2018) Mitsutaka Osawa et al.   JOURNAL OF GASTROENTEROLOGY

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment

(2017) Fred Poordad et al.   HEPATOLOGY

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

(2017) Hidenori Toyoda et al.   HEPATOLOGY

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

(2017) Kazuaki Chayama et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

(2017) Hiromitsu Kumada et al.   JOURNAL OF GASTROENTEROLOGY

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

(2017) Stefan Zeuzem et al.   JOURNAL OF HEPATOLOGY

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

(2017) Paul Y. Kwo et al.   JOURNAL OF HEPATOLOGY

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

(2017) Xavier Forns et al.   LANCET INFECTIOUS DISEASES

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

(2017) Edward Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatitis C virus infection

(2017) Michael P. Manns et al.   Nature Reviews Disease Primers

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

(2016) Edward Gane et al.   GASTROENTEROLOGY

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

(2016) Christoph Sarrazin et al.   GASTROENTEROLOGY

Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India

(2016) SubratKumar Acharya et al.   INDIAN JOURNAL OF MEDICAL RESEARCH

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

(2016) Christoph Sarrazin   JOURNAL OF HEPATOLOGY

Real-World Evidence — What Is It and What Can It Tell Us?

(2016) Rachel E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

(2015) Graham R. Foster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis

(2014) Ali A Mokdad et al.   BMC Medicine

Global distribution and prevalence of hepatitis C virus genotypes

(2014) Jane P. Messina et al.   HEPATOLOGY